Tonix Pharmaceuticals (NASDAQ:TNXP) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of Tonix Pharmaceuticals (NASDAQ:TNXP) in a research note released on Wednesday. The brokerage issued a sell rating on the stock.

Separately, Alliance Global Partners upped their price target on shares of Tonix Pharmaceuticals from $6.00 to $11.00 and gave the stock a buy rating in a research report on Monday, July 22nd.

Tonix Pharmaceuticals Price Performance

Shares of Tonix Pharmaceuticals stock opened at $0.15 on Wednesday. The company has a fifty day moving average price of $0.39 and a 200 day moving average price of $3.66. The company has a current ratio of 1.15, a quick ratio of 0.72 and a debt-to-equity ratio of 0.13. Tonix Pharmaceuticals has a twelve month low of $0.13 and a twelve month high of $27.52. The stock has a market cap of $3.25 million, a price-to-earnings ratio of 0.00 and a beta of 2.09.

Tonix Pharmaceuticals (NASDAQ:TNXP) last announced its quarterly earnings results on Friday, August 16th. The company reported ($19.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($9.91) by ($9.37). Tonix Pharmaceuticals had a negative return on equity of 158.27% and a negative net margin of 1,196.11%. The business had revenue of $2.21 million for the quarter, compared to analysts’ expectations of $3.50 million. Equities research analysts forecast that Tonix Pharmaceuticals will post -12.37 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Tonix Pharmaceuticals

An institutional investor recently raised its position in Tonix Pharmaceuticals stock. Acadian Asset Management LLC grew its stake in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) by 260.6% during the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 335,373 shares of the company’s stock after purchasing an additional 242,358 shares during the quarter. Acadian Asset Management LLC owned approximately 0.40% of Tonix Pharmaceuticals worth $61,000 as of its most recent filing with the SEC. 82.26% of the stock is owned by institutional investors and hedge funds.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.